Phosphate binders in patients with chronic kidney disease.

about

Phosphate binders in patients with chronic kidney disease.

Item

http://www.wikidata.org/entity/Q39155279

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Phosphate binders in patients with chronic kidney disease.

@en

Phosphate binders in patients with chronic kidney disease.

@nl

type

Item

label

Phosphate binders in patients with chronic kidney disease.

@en

Phosphate binders in patients with chronic kidney disease.

@nl

prefLabel

Phosphate binders in patients with chronic kidney disease.

@en

Phosphate binders in patients with chronic kidney disease.

@nl

P1476

Phosphate binders in patients with chronic kidney disease

@en

P2093

David W Johnson

http://www.w3.org/2001/XMLSchema#string

David W Mudge

http://www.w3.org/2001/XMLSchema#string

Kenneth Au

http://www.w3.org/2001/XMLSchema#string

Peter I Pillans

http://www.w3.org/2001/XMLSchema#string

Samuel Chan

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphate binders for preventing and treating bone disease in chronic kidney disease patients

Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients.

Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats.

Chewability testing in the development of a chewable tablet for hyperphosphatemia.

The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro.

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.

Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study.

P304

10-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18773/AUSTPRESCR.2017.002

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ross S Francis

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28246429

http://www.w3.org/2001/XMLSchema#string

P932

5313253

http://www.w3.org/2001/XMLSchema#string